About Venaxis
Venaxis is a publicly listed company based in Castle Rock (United States) founded in 2012. In vitro diagnostic tests for appendicitis are developed by Venaxis. Venaxis has raised $1.95 million across 1 funding round. Venaxis has completed 1 acquisition, including Riot Platforms. Its chief executive, as recorded, is Steve Lundy. Its focus areas include Life Sciences, Gastroenterology, In Vitro Diagnostic Tests and Bowel Disease. Its competitors include Gemelli Biotech and Chosen Diagnostics; 1 of its 2 listed competitors has raised funding.
Company details
Venaxis was founded in 2012 and is based in Castle Rock, United States. Operations center on the medical diagnostics sector, where in vitro tests for appendicitis are developed. The APPY1 Test, a multi-biomarker diagnostic tool, is provided to assess patient risk for appendicitis. Leadership is held by Steve Lundy as President and CEO. The companys domain is venaxis.com.
- Headquarters Castle Rock, United States
- Stage Public
- SectorsHealthcare
- Website venaxis.com
- Social LinkedIn
- Total Equity Funding$1.95M (USD)
in 1 rounds
- Latest Funding Round$1.95M (USD), Seed
Sep 2016
- Investments & Acquisitions
Funding Insights of Venaxis
Venaxis has successfully raised a total of $1.95M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.95 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.95M
- Total Rounds 1
- Last Round Seed — $1.95M
- First Round $1.95M
(Sep 2016)
All 1 funding rounds of Venaxis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $1.95M | Seed | – | – | – |
People of Venaxis
1 people are tracked at Venaxis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Steve Lundy | President & CEO | Leadership |
Complete people profiles for Venaxis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Venaxis
Venaxis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Riot Platforms.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bitcoin mining solutions are offered by the platform. | riotplatforms.com | Castle Rock, United States | 2000 | Sep 2016 | •••• |
Complete acquisition details for Venaxis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Venaxis
3 dated milestones of Venaxis across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Venaxis is founded.
- Funding First funding round of $1.9M.
- Acquisition Acquires Riot Platforms.
Competitors of Venaxis
Venaxis has 2 listed competitors in our database, 1 of them funded. They include Gemelli Biotech and Chosen Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gemellibiotech.com | 2018 | Los Angeles, United States | $23.03M | Diagnostics and therapeutics for the human microbiome are provided. | ||
| chosendiagnostics.com | 2011 | New Orleans, United States | Developing a novel MDx kit to diagnose a severe bowel disorder in premature infants |
Detailed competitors of Venaxis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Venaxis (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Venaxis
Complete news archive for Venaxis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Venaxis
Venaxis was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Venaxis is headquartered in Castle Rock, United States. It is registered at Castle Rock, Colorado, United States.
Steve Lundy is the CEO of Venaxis, as recorded in our data.
Venaxis is a funded company, having raised a total of $1.95M across 1 funding round to date. The company's 1st funding round was a Seed of $1.95M, raised on Sep 2016.
Venaxis was founded in 2012 and is based in Castle Rock, United States. Operations center on the medical diagnostics sector, where in vitro tests for appendicitis are developed. The APPY1 Test, a multi-biomarker diagnostic tool, is provided to assess patient risk for appendicitis. Leadership is held by Steve Lundy as President and CEO. The companys domain is venaxis.com.
Venaxis's top competitors include Gemelli Biotech and Chosen Diagnostics.
Venaxis has made 1 acquisition, including Riot Platforms.